Zydus Cadila is a drug firm based in India which has been permitted to start their first clinical based trials of developed novel molecule XYIL1 by the Drugs Controller General of India. The ZYIL1 is said to be used for inflammation condition NLRP3. NLRP3 is the condition where harmful inflammation takes place inside the body which further leads to diseases like Acute Respiratory Distress Syndrome, Cardiovascular diseases, Gastro-intestinal diseases, Renal diseases and more. The firm is now going to start trials on healthy individuals.
Zydus Cadila gets DCGI approval to begin trials of XYIL1
